Sarepta Therapeutics, Inc.SRPTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +65.94% | +80.15% | +68.38% | -14.52% | -32.73% |
| Gross Profit Growth | +49.21% | +67.34% | +44.02% | -33.80% | -91.59% |
| EBITDA Growth | +227.63% | -778.90% | +525.58% | -444.83% | -235.10% |
| Operating Income Growth | +556.57% | -960.58% | +0.00% | -565.80% | -354.56% |
| Net Income Growth | +248.37% | -1338.98% | +2947.86% | -635.38% | -277.84% |
| EPS Growth | +236.73% | -1310.53% | +2771.43% | -614.29% | -266.06% |
| EPS Diluted Growth | +248.84% | -1343.24% | +2600.00% | -645.45% | -362.00% |
| Weighted Average Shares Growth | +2.85% | +3.59% | +3.58% | +5.08% | +8.84% |
| Weighted Average Shares Diluted Growth | +2.73% | -1.77% | +7.54% | -0.21% | -3.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +1649.01% | +0.00% | +42.54% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +132.33% |
| Receivables Growth | +48.69% | +72.76% | +55.41% | +4.96% | -38.71% |
| Inventory Growth | +132.29% | +152.04% | +104.62% | +90.34% | +21.97% |
| Asset Growth | +21.40% | +7.47% | +7.46% | -2.96% | -15.48% |
| Book Value per Share Growth | +72.86% | +14.77% | +21.67% | +2.88% | -31.40% |
| Debt Growth | -3.85% | -2.58% | -1.17% | -10.55% | -22.60% |
| R&D Expense Growth | +2.27% | +285.96% | +13.75% | -2.49% | +62.71% |
| SG&A Expenses Growth | +24.43% | +5.22% | -0.65% | -28.32% | -21.71% |